CAR’TCR-T Cells Co-Expressing CD33-CAR and dNPM1-TCR as Superior Dual-Targeting Approach for AML Treatment

CAR’TCR-T cells, co-expressing a CD33-CAR and a transgenic dNPM1-TCR, revealed increased and prolonged anti-tumor activity in vitro, particularly in case of low target antigen expression.